High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant Acinetobacter baumannii: An Observational Cohort Study.

Hui HanWeidong QinYue ZhengDongming CaoHaining LuLu ZhangYi CuiYuanyuan HuWei LiHaipeng GuoDawei WuChen LiHao WangYuguo Chen

Published in: Infection and drug resistance (2021)

A tigecycline dose that is twice its standard dose is better for the treatment of XDR-AB infection only in BSI associated with non-pulmonary infection.

Keyphrases

acinetobacter baumannii
drug resistant
multidrug resistant
high dose
pseudomonas aeruginosa
klebsiella pneumoniae
pulmonary hypertension
combination therapy
stem cell transplantation
replacement therapy